ApoGen Biotechnologies Garners $7,000,000 Series A Financing

  • Feed Type
  • Date
    12/13/2016
  • Company Name
    ApoGen Biotechnologies
  • Mailing Address
    1616 Eastlake Ave E. Seattle, WA 98102 USA
  • Company Description
    ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutation. ApoGen is building upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug resistance.
  • Website
    http://www.apogenbiotech.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $7,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    We are excited to invest Accelerator’s unique startup resources to potentially develop these promising technologies for cancer patients in need.
  • M&A Terms
  • Venture Investor
    AbbVie Biotech Ventures
  • Venture Investor
    Alexandria Venture Investments
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    WRF Capital
  • Venture Investor
    WuXi PharmaTech

Trending on Xconomy